Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER’S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

DOI

  1. APOE and dementia - resequencing and genotyping in 105,597 individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Shift work and incidence of dementia: A Danish Nurse Cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Declining incidence of dementia: A national registry-based study over 20 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Changes in the lipidome in type 1 diabetes following low carbohydrate diet: Post-hoc analysis of a randomized crossover trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Min Kim
  • Stuart G Snowden
  • Tahmina Ahmad
  • S. Westwood
  • Alison Baird
  • Petroula Proitsi
  • Alejo Nevado-Holgado
  • Abdul Hye
  • N. J. Ashton
  • Isabelle Bos
  • Stephanie J B Vos
  • Rik Vandenberghe
  • Philip Scheltens
  • Sebastiaan Engelborghs
  • Giovanni B Frisoni
  • José Luis Molinuevo
  • Anders Wallin
  • Alberto Lleo
  • Julius Popp
  • Pablo Martinez-Lage
  • Lars Bertram
  • Frederik Barkhof
  • Henrik Zetterberg
  • Johannes Streffer
  • Pieter Jelle Visser
  • Simon Lovestone
  • Cristina Legido-Quigley
Vis graf over relationer
Background Alzheimer’s disease (AD) is a progressive neurological disease that is irreversible. A critical and as-yet unmet need in AD is the discovery of peripheral molecules that can act as biomarkers in the early stages of AD. Given that brain pathology precedes clinical symptom onset, small molecule markers associated to pathology could provide new potential drug targets and molecules that are relatively easy to measure. Here in this study, we employed a targeted metabolomics approach to identify metabolites associated with levels of amyloid. Methods This study analysed 593 plasma samples selected from the EMIF catalogue where participants were selected as cognitively healthy (n=242), mild cognitive impairment (n=236) and AD (n=115) at the time of blood collection. Of these, 225 participants were amyloid negative while 368 were amyloid positive. Targeted metabolomics was carried out and the levels of 883 metabolites were measured. Logistic and linear regressions models were adjusted to covariates and multiple comparisons and the primary outcome was amyloid burden in CSF. Results Logistic regression models revealed elevated levels of 34 metabolites and diminished levels of 27 metabolites in the plasma of amyloid positive participants (at p<0.05 level). From those, seven metabolites passed false discovery rate correction and all 4 primary fatty acid amides (PFAMs) measured in this study were found to be among the highest ranked (all OR>2.3, FDR q<0.005). Subsequent linear regression analyses was carried out, which also revealed levels of the 4 amides to be strongly associated with amyloid levels (all 0.7>β>0.3, FDR q<0.005). The mechanisms behind endogenous PFAMs are largely unknown but reports propose that they can be synthesised exclusively in brain and cause sedation via cannabinoid receptors. Conclusions PFAMs have been found increased and associated to Aβ burden, suggesting that primary fatty amides not only have multiple effects on the central nervous system but that might have an important role in the early and late stages of AD.
OriginalsprogEngelsk
TidsskriftAlzheimer's & Dementia
Vol/bind14
Udgave nummer7
Sider (fra-til)1161-1161
Antal sider1
ISSN1552-5260
DOI
StatusUdgivet - 1 jul. 2018
BegivenhedAAIC18: Alzheimer’s Association International Conference 2018 - McCormick Place, Chicago, USA
Varighed: 22 jul. 201826 jul. 2018
https://www.alzdiscovery.org/events/event/aaic-2018

Konference

KonferenceAAIC18
LokationMcCormick Place
LandUSA
ByChicago
Periode22/07/201826/07/2018
Internetadresse

Begivenhed

AAIC18: Alzheimer’s Association International Conference 2018

22/07/201826/07/2018

Chicago, USA

Begivenhed: Konference

ID: 55541179